402 related articles for article (PubMed ID: 32390113)
21. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
22. The significance of concurrent MYC and BCL2 expression in Egyptian patients with diffuse large B-cell NHL.
Abdelhamid TM; Gaber AA; Abdelfattah RM; Algamal DA; Hamdy O; Mohamed G
Pathol Res Pract; 2024 Jan; 253():154973. PubMed ID: 38101156
[TBL] [Abstract][Full Text] [Related]
23. Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein.
Hu K; Gao JJ; Li QH; Tian L; Wan W; Zhao W; Wang JJ; Fu L
Kaohsiung J Med Sci; 2019 Jul; 35(7):425-431. PubMed ID: 31050117
[TBL] [Abstract][Full Text] [Related]
24. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
25. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
26. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H; Miura K; Nakagawa M; Sugitani M; Amano Y; Kurita D; Sakagami M; Ohtake S; Uchino Y; Kodaira H; Iriyama N; Kobayashi S; Hojo A; Kobayashi Y; Hirabayashi Y; Kusuda M; Hatta Y; Nakayama T; Takei M
Leuk Lymphoma; 2016 Dec; 57(12):2784-2790. PubMed ID: 27071312
[TBL] [Abstract][Full Text] [Related]
27. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
28. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
[TBL] [Abstract][Full Text] [Related]
29. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
30. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
[TBL] [Abstract][Full Text] [Related]
31. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
32. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
[TBL] [Abstract][Full Text] [Related]
33. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
34. BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.
Roh J; Cho H; Pak HK; Lee YS; Lee SW; Ryu JS; Chae EJ; Kim KW; Huh J; Choi YS; Jeong SH; Suh C; Yoon DH; Park CS
Mod Pathol; 2022 Apr; 35(4):480-488. PubMed ID: 34764434
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.
Johnson PWM; Balasubramanian S; Hodkinson B; Shreeve SM; Sun S; Srinivasan S; Steele AJ; Vermeulen J; Sehn LH; Wilson WH
Blood Adv; 2023 May; 7(10):2008-2017. PubMed ID: 36696540
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
37. Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Kawashima I; Inamoto Y; Maeshima AM; Nomoto J; Tajima K; Honda T; Shichijo T; Kawajiri A; Takemura T; Onishi A; Ito A; Tanaka T; Fuji S; Kurosawa S; Kim SW; Maruyama D; Tobinai K; Kobayashi Y; Fukuda T
Biol Blood Marrow Transplant; 2018 Feb; 24(2):294-300. PubMed ID: 29037890
[TBL] [Abstract][Full Text] [Related]
38. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
[TBL] [Abstract][Full Text] [Related]
39. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.
Inano S; Iwasaki M; Iwamoto Y; Sueki Y; Fukunaga A; Yanagita S; Arima N
Int J Hematol; 2014 Feb; 99(2):162-8. PubMed ID: 24338743
[TBL] [Abstract][Full Text] [Related]
40. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
